Ernexa completes second closing of $6M private placement; total $7M raised; expects to regain Nasdaq compliance

Ernexa Therapeutics Inc.

Second closing on June 9, 2025: issued 47.7M shares and 9.3M pre-funded warrants for ~$6.0M gross proceeds.
Combined with April 2 closing, total 57.7M shares and 9.8M warrants issued for ~$7.0M.
Proceeds to be used for working capital and repaying certain notes.
Company believes it now satisfies Nasdaq Stockholders' Equity Standard ($2.5M minimum) as alternative to Market Value Standard.
Pre-funded warrants exercisable at $0.005 per share with 4.99%/9.99% beneficial ownership limitation.

item 3.02item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.